Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.
Number of peer-reviewed scientific papers
Number of projects completed
Number of patents and patent pending
Number of conferences
Valérie has 14-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGen’s technology.
Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.
Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.
Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.
Valérie is currently the sole board member of NexPlasmaGen. New members will be added as we growth the company.
At the moment, no advisory board has been formed. To come soon!